PEG-interferon α-2b plus ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon A or interferon α-2b plus ribavirin therapy.

被引：0
|
作者：
Sulkowski, M
Rothstein, KD
Stein, L
Godofsky, E
Shoultz, D
Hudnall, R
Huff, M
Dieterich, D
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[2] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] PPD Dev, Seattle, WA USA
[5] Hepatitis Resource Network, Tacoma, WA USA
[6] NYU, Sch Med, New York, NY USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
987
引用
下载
收藏
页码：419A / 419A
页数：1
相关论文
共 50 条
  • [21] THERAPEUTIC RESPONSE TO PEG-INTERFERON PLUS RIBAVIRIN IN CHRONIC HEPATITIS C
    Harja-Alexa, Ioana-Alina
    Luca, Mihaela-Catalina
    Manciuc, Carmen Doina
    Vata, A.
    Badescu, Aida
    Hurmuzache, M. E.
    Ciocan, Alexandra Mirela
    Hunea, Ioana Maria
    Trofin, Felicia
    Iancu, Luminita Smaranda
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2019, 123 (04): : 615 - 622
  • [22] Prospective study on early virologic response to treatment with interferon α-2b plus ribavirin in patients with chronic hepatitis C genotype 1b
    Nagaki, M
    Imose, M
    Naiki, T
    Kimura, K
    Hayashi, H
    Shimizu, M
    Ohnishi, H
    Tomita, E
    Sugihara, J
    Amano, K
    Sakai, T
    Kojima, T
    Katsumura, N
    Kondo, Y
    Fujmoto, M
    Moriwaki, H
    HEPATOLOGY RESEARCH, 2005, 33 (04) : 285 - 291
  • [23] Early virologic response value as predictive factor of sustained virologic response to treatment with interferon α-2b plus ribavirin in chronic hepatitis C patients with or without HIV coinfection
    Buenestado-Garcia, Juan
    Rubio-Rivas, Manuel
    Rene-Espinet, Josep Maria
    Pinol-Felis, Carmen
    Egido-Garcia, Ramon
    Rubio-Caballero, Manuel
    MEDICINA CLINICA, 2006, 127 (15): : 561 - 566
  • [24] Pegylated interferon alpha 2b (PEG-IFN) plus ribavirin (RBV) versus pegylated interferon alpha 2b for chronic hepatitis C in HIV patients
    Cargnel, A
    Angeli, E
    Mainini, A
    Gubertini, G
    Giorgi, R
    Orlando, G
    Duca, P
    GASTROENTEROLOGY, 2003, 124 (04) : A766 - A766
  • [25] Combination Therapy with Interferon-α2b, Ribavirin, and Amantadine in Chronic Hepatitis C Nonresponders to Interferon and Ribavirin
    Paul J. Thuluvath
    Hemant Pande
    Joyce Maygers
    Digestive Diseases and Sciences, 2003, 48 : 594 - 597
  • [26] Combination therapy with interferon-α2b, ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin
    Thuluvath, PJ
    Pande, H
    Maygers, J
    DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (03) : 594 - 597
  • [27] Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg-interferon alfa-2b plus ribavirin
    McHutchison, J
    Manns, M
    Harvey, J
    Albrecht, JK
    JOURNAL OF HEPATOLOGY, 2001, 34 : 2 - 3
  • [28] Treatment with amantadine plus ribavirin plus interferon in patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy.
    Ferenci, P
    Stauber, R
    Hackl, F
    Schuetze, K
    Bauer, B
    Datz, C
    GASTROENTEROLOGY, 2000, 118 (04) : A1437 - A1437
  • [29] Interferon alfacon-1 and ribavirin versus interferon α-2b and ribavirin in the treatment of chronic hepatitis C
    Sjogren, MH
    Sjogren, R
    Holtzmuller, K
    Winston, B
    Butterfield, B
    Drake, S
    Watts, A
    Howard, R
    Smith, M
    DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (04) : 727 - 732
  • [30] Pegylated interferon α-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients
    Voigt, Esther
    Schulz, Christian
    Klausen, Gerd
    Goelz, Joerg
    Mauss, Stefan
    Schmutz, Guenther
    Jessen, Heiko
    Weitner, Lutwin
    Mutz, Antonius
    Schranz, Dietmar
    Rockstroh, Juergen K.
    JOURNAL OF INFECTION, 2006, 53 (01) : 36 - 42
12345